Abstract | OBJECTIVES: METHODS: RESULTS: CONCLUSION: The results found here warrant further studies and may help in the design of new protocols geared to the treatment of high risk neuroblastomas.
|
Authors | Jitka Poljakova, Jana Hrebackova, Marketa Dvorakova, Michaela Moserova, Tomas Eckschlager, Jan Hrabeta, Marketa Göttlicherova, Barbora Kopejtkova, Eva Frei, Rene Kizek, Marie Stiborova |
Journal | Neuro endocrinology letters
(Neuro Endocrinol Lett)
Vol. 32 Suppl 1
Pg. 101-16
( 2011)
ISSN: 0172-780X [Print] Sweden |
PMID | 22167207
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Ellipticines
- Histone Deacetylase Inhibitors
- Hydroxamic Acids
- ellipticine
- trichostatin A
- Valproic Acid
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology, therapeutic use)
- Brain Neoplasms
(drug therapy, genetics, pathology)
- DNA Damage
- Dose-Response Relationship, Drug
- Drug Evaluation, Preclinical
- Ellipticines
(administration & dosage, pharmacology)
- Histone Deacetylase Inhibitors
(administration & dosage, pharmacology)
- Humans
- Hydroxamic Acids
(administration & dosage, pharmacology)
- Microsomes, Liver
(drug effects, metabolism)
- Models, Biological
- Neuroblastoma
(drug therapy, genetics, pathology)
- Rats
- Treatment Outcome
- Tumor Cells, Cultured
- Valproic Acid
(administration & dosage, pharmacology)
|